MEMBER'S LOGINX
| Login Failure | ||||||||
|
||||||||
| Sign Up | Forgot Password? | ||||||||
- Home
- Research It
- Compare Company
- International - mnc pharma
- NOVARTIS - MYLAN (US)
NOVARTIS vs MYLAN (US) - Comparison Results
NOVARTIS 
Change
Novartis is a 76% subsidiary of Novartis AG - Switzerland and has a countrywide presence in the healthcare business. While pharmaceuticals contributes 70% to total revenues (FY10), generics (6%), consumer healthcare i.e. OTC (14%) and animal health (... More
MYLAN (US)
Mylan is one of the world’s leading generics and specialty pharmaceutical company. Its products span to customers in about 140 countries across the world. The company maintains one of the industry’s broadest and highest quality product portfolios, wh... More
Financials
 NOVARTIS  MYLAN |
| EQUITY SHARE DATA | |||||
|---|---|---|---|---|---|
| NOVARTIS Mar-18 |
MYLAN Dec-14 |
NOVARTIS/ MYLAN |
5-Yr Chart Click to enlarge
|
||
| High | Rs | 758 | 4,292 | - | |
| Low | Rs | 579 | 3,025 | - | |
| Sales per share (Unadj.) | Rs | 228.4 | 1,469.4 | - | |
| Earnings per share (Unadj.) | Rs | 31.7 | 177.0 | - | |
| Cash flow per share (Unadj.) | Rs | 32.8 | 284.9 | - | |
| Dividends per share (Unadj.) | Rs | 10.00 | 0 | - | |
| Dividend yield (eoy) | % | 1.5 | 0 | - | |
| Book value per share (Unadj.) | Rs | 297.1 | 730.5 | - | |
| Shares outstanding (eoy) | m | 24.69 | 378.37 | - | |
| Bonus/Rights/Conversions | - | OI | - | ||
| Price / Sales ratio | x | 2.9 | 2.5 | 117.6% | |
| Avg P/E ratio | x | 21.1 | 20.7 | 101.9% | |
| P/CF ratio (eoy) | x | 20.4 | 12.8 | 158.9% | |
| Price / Book Value ratio | x | 2.2 | 5.0 | 44.9% | |
| Dividend payout | % | 31.5 | 0 | - | |
| Avg Mkt Cap | Rs m | 16,505 | 1,384,310 | 1.2% | |
| No. of employees | `000 | 0.7 | 25.0 | 2.7% | |
| Total wages/salary | Rs m | 1,445 | 0 | - | |
| Avg. sales/employee | Rs Th | 8,441.3 | 22,239.8 | 38.0% | |
| Avg. wages/employee | Rs Th | 2,163.6 | 0 | - | |
| Avg. net profit/employee | Rs Th | 1,173.1 | 2,679.1 | 43.8% | |
| INCOME DATA | |||||
|---|---|---|---|---|---|
| Net Sales | Rs m | 5,639 | 555,994 | 1.0% | |
| Other income | Rs m | 1,718 | -3,241 | -53.0% | |
| Total revenues | Rs m | 7,357 | 552,754 | 1.3% | |
| Gross profit | Rs m | -63 | 138,278 | -0.0% | |
| Depreciation | Rs m | 25 | 40,835 | 0.1% | |
| Interest | Rs m | 55 | 23,983 | 0.2% | |
| Profit before tax | Rs m | 1,575 | 70,220 | 2.2% | |
| Minority Interest | Rs m | 0 | -288 | 0.0% | |
| Prior Period Items | Rs m | 0 | 0 | - | |
| Extraordinary Inc (Exp) | Rs m | 0 | 0 | - | |
| Tax | Rs m | 792 | 2,953 | 26.8% | |
| Profit after tax | Rs m | 784 | 66,979 | 1.2% | |
| Gross profit margin | % | -1.1 | 24.9 | -4.5% | |
| Effective tax rate | % | 50.3 | 4.2 | 1,195.1% | |
| Net profit margin | % | 13.9 | 12.0 | 115.4% | |
| BALANCE SHEET DATA | |||||
|---|---|---|---|---|---|
| Current assets | Rs m | 9,522 | 488,793 | 1.9% | |
| Current liabilities | Rs m | 3,296 | 382,138 | 0.9% | |
| Net working cap to sales | % | 110.4 | 19.2 | 575.5% | |
| Current ratio | x | 2.9 | 1.3 | 225.8% | |
| Inventory Days | Days | 37 | 78 | 46.9% | |
| Debtors Days | Days | 28 | 107 | 26.5% | |
| Net fixed assets | Rs m | 46 | 128,628 | 0.0% | |
| Share capital | Rs m | 123 | 19,661 | 0.6% | |
| Net worth | Rs m | 7,336 | 276,384 | 2.7% | |
| Long term debt | Rs m | 0 | 412,891 | 0.0% | |
| Total assets | Rs m | 11,105 | 1,113,249 | 1.0% | |
| Interest coverage | x | 29.5 | 3.9 | 750.6% | |
| Debt to equity ratio | x | 0 | 1.5 | 0.0% | |
| Sales to assets ratio | x | 0.5 | 0.5 | 101.7% | |
| Return on assets | % | 7.6 | 8.2 | 92.5% | |
| Return on equity | % | 10.7 | 24.2 | 44.1% | |
| Return on capital | % | 22.2 | 13.6 | 163.1% | |
| CASH FLOW | |||||
|---|---|---|---|---|---|
| From Operations | Rs m | 1,610 | 73,086 | 2.2% | |
| From Investments | Rs m | 687 | -57,638 | -1.2% | |
| From Financial Activity | Rs m | -2,677 | -19,258 | 13.9% | |
| Net Cashflow | Rs m | -380 | -3,810 | 10.0% | |
The reporting currency for MYLAN (US) is United States Dollars. All data has been converted at 72.02 Rs / USD
Compare NOVARTIS With: ADCOCK INGRAM (S. Africa) ACTAVIS (US) TEVA PHARMA (Israel)
Compare NOVARTIS With: ALEMBIC LTD TTK HEALTHCARE STRIDES PHARMA SCIENCE WYETH LTD CADILA HEALTHCARE
|
| |
Today's Market
From Urjit Patel to Shaktikanta Das; What Lies Ahead?(Podcast)
The week gone by saw Sensex plunge from 700 points to rise by over 600 points. With a volatile and eventful week, it was a challenge keeping up with the news every day.
Related Views On News
NOVARTIS Announces Quarterly Results (2QFY19); Net Profit Down 64.1% (Quarterly Result Update)
Nov 21, 2018 | Updated on Nov 21, 2018For the quarter ended September 2018, NOVARTIS has posted a net profit of Rs 94 m (down 64.1% YoY). Sales on the other hand came in at Rs 1 bn (down 36.4% YoY). Read on for a complete analysis of NOVARTIS's quarterly results.
NOVARTIS Announces Quarterly Results (1QFY19); Net Profit Up 42.2% (Quarterly Result Update)
Jul 30, 2018 | Updated on Jul 30, 2018For the quarter ended June 2018, NOVARTIS has posted a net profit of Rs 100 m (up 42.2% YoY). Sales on the other hand came in at Rs 1 bn (up 20.3% YoY). Read on for a complete analysis of NOVARTIS's quarterly results.
Aster DM Healthcare (IPO)
Feb 10, 2018Should you subscribe to the IPO of Aster DM Healthcare Ltd?
Shalby Ltd. (IPO)
Dec 2, 2017Should you subscribe to the IPO of Shalby Ltd?
The Power of 5 Minutes (The 5 Minute Wrapup)
Jun 16, 2017Here's what you can expect from The 5 Minute Wrapup in the coming months and years.
More Views on NewsMost Popular
4 Rebound Stocks to Profit from the Current Small Cap Crash(Profit Hunter)
Dec 3, 2018Indian small cap space is offering a discount season. Make sure you do not get too late to scoop up the bargains.
It's Almost the Perfect Time to Buy This Safe Stock(The 5 Minute Wrapup)
Dec 6, 2018My latest StockSelect recommendation ticks all the boxes of a great safe stock.
Looking For Higher Interest Rates on Bank FDs? Read This!(Outside View)
Dec 5, 2018Credit disbursement to the productive sectors of the economy such as infrastructure, engineering, food processing, textiles, and chemicals, among others is rising.
Are Foreign Investors Heading Back to the Indian Stock Markets?(Chart Of The Day)
Dec 3, 2018After months of heavy FII selling, November witnessed a return on foreign money into Indian equities...
DSP Mutual Fund's Sale of DHFL Bonds: Here's What You Need to Know(Outside View)
Dec 5, 2018PersonalFN explains the probable reason as to why the capital market regulator has initiated DSP Mutual Fund's bond sale that caused DHFL stock to crash.
More|
| |
NOVARTIS SHARE PRICE
Dec 14, 2018 (Close)
TRACK NOVARTIS
- Track your investment in NOVARTIS with Equitymaster's Portfolio Tracker. Set live price alerts, get research alerts and more. Get access now...
- Add To MyStocks
MORE ON NOVARTIS
NOVARTIS 8-QTR ANALYSIS
COMPARE NOVARTIS WITH
OTHER USEFUL LINKS
MARKET STATS
ABOUT EQUITYMASTER
Since 1996, Equitymaster has been the source for honest and credible opinions on investing in India. With solid research and in-depth analysis Equitymaster is dedicated towards making its readers- smarter, more confident and richer every day. Here's why hundreds of thousands of readers spread across more than 70 countries Trust Equitymaster.
FREE NEWSLETTERS
PREMIUM PRODUCTS
QUICK LINKS
APPS
FOLLOW
Copyright © Equitymaster Agora Research Private Limited.
Whitelist | Refer | Terms | Privacy | Contact | About | Sitemap
Equitymaster Agora Research Private Limited. 103, Regent Chambers, Above Status Restaurant, Nariman Point, Mumbai - 400 021. India.
Telephone: +91-22-61434055. Fax: +91-22-22028550. Email: info@equitymaster.com. Website: www.equitymaster.com. CIN:U74999MH2007PTC175407
All rights reserved. Any act of copying, reproducing or distributing this newsletter whether wholly or in part, for any purpose without the permission of Equitymaster is strictly prohibited and shall be deemed to be copyright infringement.
LEGAL DISCLAIMER: Equitymaster Agora Research Private Limited (hereinafter referred as 'Equitymaster') is an independent equity research Company. Equitymaster is not an Investment Adviser. Information herein should be regarded as a resource only and should be used at one's own risk. This is not an offer to sell or solicitation to buy any securities and Equitymaster will not be liable for any losses incurred or investment(s) made or decisions taken/or not taken based on the information provided herein. Information contained herein does not constitute investment advice or a personal recommendation or take into account the particular investment objectives, financial situations, or needs of individual subscribers. Before acting on any recommendation, subscribers should consider whether it is suitable for their particular circumstances and, if necessary, seek an independent professional advice. This is not directed for access or use by anyone in a country, especially, USA, Canada or the European Union countries, where such use or access is unlawful or which may subject Equitymaster or its affiliates to any registration or licensing requirement. All content and information is provided on an 'As Is' basis by Equitymaster. Information herein is believed to be reliable but Equitymaster does not warrant its completeness or accuracy and expressly disclaims all warranties and conditions of any kind, whether express or implied. Equitymaster may hold shares in the company/ies discussed herein. As a condition to accessing Equitymaster content and website, you agree to our Terms and Conditions of Use, available here. The performance data quoted represents past performance and does not guarantee future results.
SEBI (Research Analysts) Regulations 2014, Registration No. INH000000537.